Current knowledge on psoriasis and autoimmune diseases
- PMID: 29387591
- PMCID: PMC5683130
- DOI: 10.2147/PTT.S64950
Current knowledge on psoriasis and autoimmune diseases
Abstract
Psoriasis is a prevalent, chronic inflammatory disease of the skin, mediated by crosstalk between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen presenting cells (APCs) and T cells. Exclusive cellular "responsibility" for the induction and maintenance of psoriatic plaques has not been clearly defined. Increased proliferation of keratinocytes and endothelial cells in conjunction with APC/T cell/monocyte/macrophage inflammation leads to the distinct epidermal and vascular hyperplasia that is characteristic of lesional psoriatic skin. Despite the identification of numerous susceptibility loci, no single genetic determinant has been identified as responsible for the induction of psoriasis. Thus, numerous other triggers of disease, such as environmental, microbial and complex cellular interactions must also be considered as participants in the development of this multifactorial disease. Recent advances in therapeutics, especially systemic so-called "biologics" have provided new hope for identifying the critical cellular targets that drive psoriasis pathogenesis. Recent recognition of the numerous co-morbidities and other autoimmune disorders associated with psoriasis, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus suggest common signaling elements and cellular mediators may direct disease pathogenesis. In this review, we discuss common cellular pathways and participants that mediate psoriasis and other autoimmune disorders that share these cellular signaling pathways.
Keywords: autoimmunity; immunosuppression; psoriasis.
Conflict of interest statement
Disclosure The authors have no conflict of interest to disclose.
Figures

Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities.Cytokine. 2013 May;62(2):195-201. doi: 10.1016/j.cyto.2013.03.013. Epub 2013 Apr 4. Cytokine. 2013. PMID: 23562549 Free PMC article. Review.
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
Cited by
-
Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study.J Int Med Res. 2021 Apr;49(4):3000605211004039. doi: 10.1177/03000605211004039. J Int Med Res. 2021. PMID: 33900870 Free PMC article.
-
Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems.Antioxidants (Basel). 2024 Jul 28;13(8):912. doi: 10.3390/antiox13080912. Antioxidants (Basel). 2024. PMID: 39199158 Free PMC article. Review.
-
Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients.Ther Clin Risk Manag. 2016 Oct 21;12:1579-1585. doi: 10.2147/TCRM.S113769. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27799779 Free PMC article.
-
Effect of Melatonin on Psoriatic Phenotype in Human Reconstructed Skin Model.Biomedicines. 2022 Mar 23;10(4):752. doi: 10.3390/biomedicines10040752. Biomedicines. 2022. PMID: 35453501 Free PMC article.
-
Current Concepts of Psoriasis Immunopathogenesis.Int J Mol Sci. 2021 Oct 26;22(21):11574. doi: 10.3390/ijms222111574. Int J Mol Sci. 2021. PMID: 34769005 Free PMC article. Review.
References
-
- Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. - PubMed
-
- Cameron JB, Voohees AS. History of Psoriasis. London: Springer; 2014.
-
- Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422. - PubMed
-
- Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5):490–495. - PubMed
-
- Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous